Posted September 17, 2019
Ghosh R, Narasanna A, Wang SE, Liu S., Balko JM, Gonzalez AM, Mills GB, Penuel E, Winslow J, Sperinde J, Leitzel K, Kostler WJ, Lipton A, Bates M, and Arteaga C. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011 Mar 1;71(5):1871-82.